News

Study Finds on MSN1d
Weight Loss Showdown: Mounjaro (Tirzepatide) Trounces Wegovy in Head-to-Head Trial
In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...
MedPage Today on MSN1d
Zepbound and Wegovy Go Head to Head for Obesity: And the Winner Is ...
Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...
Zepbound tops Wegovy for weight loss in first head-to-head study comparing the drugs
Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...
Zepbound outperforms Wegovy in head-to-head weight loss study
A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...
Healio17h
Tirzepatide bests semaglutide for weight loss in adults with obesity
Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...
Eli Lilly’s Zepbound shows superior weight loss over Novo Nordisk's Wegovy in trial
Eli Lilly ( NYSE: LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ( ...
The Print on MSN1d
Mounjaro vs Wegovy: Guess which obesity drug outperformed the other by a mile in head-to-head trial
Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended ...
News Medical2d
Tirzepatide outperforms semaglutide in weight loss clinical trial
Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...